scholarly journals Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review

2016 ◽  
Vol 11 (6) ◽  
pp. 3849-3857 ◽  
Author(s):  
MEI-YI LI ◽  
XIAO-XIA HU ◽  
JIAN-HONG ZHONG ◽  
LU-LU CHEN ◽  
YONG-XIU LIN
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Early Stage ◽  
Therapeutic Role ◽  
Systematic Lymphadenectomy ◽  
Early Stage Endometrial Cancer

Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: The role of 18F-FDG PET/CT

2013 ◽  
Vol 130 (2) ◽  
pp. 306-311 ◽  
Author(s):  
Cinzia Crivellaro ◽  
Mauro Signorelli ◽  
Luca Guerra ◽  
Elena De Ponti ◽  
Cecilia Pirovano ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
High Risk ◽  
Fdg Pet ◽  
Early Stage ◽  
Systematic Lymphadenectomy ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Early Stage Endometrial Cancer

scholarly journals Controversies in the Treatment of Early Stage Endometrial Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Joshua Z. Press ◽  
Walter H. Gotlieb
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Chemotherapy ◽  
Early Stage ◽  
Sentinel Lymph Node Mapping ◽  
Optimal Management ◽  
Lymph Node Mapping ◽  
Randomized Controlled ◽  
Extent Of Surgery ◽  
Early Stage Endometrial Cancer

Despite the publication of numerous studies, including some multicentered randomized controlled trials, there continues to be vigorous debate regarding the optimal management of early stage endometrial cancer, including the extent of surgery and the role of adjuvant chemotherapy and radiation. Resolving these questions has become increasingly important in view of the increase of endometrial cancer, related to the aging population and the alarming incidence of obesity. Furthermore, there are more surgical challenges encountered when operating on elderly patients or on patients with increased BMI and the associated comorbidities, such as diabetes, hypertension, heart disease, and pulmonary dysfunction. This paper will focus on the advantages of minimally invasive surgery, the value of lymphadenectomy including sentinel lymph node mapping, and some of the current controversies surrounding adjuvant chemotherapy and radiation.

Extrapelvic Sentinel Lymph Nodes in Endometrial Cancer Patients With Unmapped Pelvic Side: A Brief Report

2018 ◽  
Vol 28 (4) ◽  
pp. 700-703 ◽  
Author(s):  
Salih Taşkin ◽  
Duygu Altin ◽  
Yavuz Emre Şükür ◽  
Firat Ortaç
Keyword(s):  
Endometrial Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Detection Rate ◽  
Near Infrared ◽  
Early Stage ◽  
Sentinel Lymph Nodes ◽  
Fluorescent Imaging ◽  
Systematic Lymphadenectomy ◽  
Early Stage Endometrial Cancer

ObjectiveThe aim of the study was to evaluate extrapelvic sentinel lymph nodes (SLNs) in clinical early-stage endometrial cancer patients with unmapped pelvic side(s) during fluorescent imaging-based sentinel mapping.Materials and MethodsEligible patients underwent sentinel mapping using cervical injection of indocyanine green and near-infrared florescent imaging compatible endoscopic systems. Pelvic SLNs were identified and resected. If bilateral mapping was not achieved, upper lymph nodes areas including presacral, upper common iliac, and para-aortic caval regions were explored for any SLN. Systematic lymphadenectomy was performed after applying SLN algorithm steps.ResultsIn 24 of 101 patients, bilateral pelvic mapping was not achieved. Bilateral unmapping was seen in 4 of 24 and unilateral pelvic side mapping in 20 of 24 patients. There was no extrapelvic SLN among 4 cases with bilateral pelvic unmapping, whereas 8 (40%) of 20 patients with unilateral pelvic mapping had extrapelvic SLNs. Five of extrapelvic SLNs were in presacral, 2 in upper common iliac, and 1 in paracaval regions.ConclusionsObserving for extrapelvic SLNs in cases with unmapped pelvic side(s) could increase detection rate of SLN mapping in clinical early-stage endometrial cancer.

The role of L1CAM in early-stage endometrial cancer recurrence

2018 ◽  
Vol 149 ◽  
pp. 61
Author(s):  
C.M. Dahl ◽  
S. Bedell ◽  
L. Uppendahl ◽  
T. Pulver ◽  
R. Hellweg ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Early Stage ◽  
Cancer Recurrence ◽  
Early Stage Endometrial Cancer

Oral Progestin Treatment for Early-Stage Endometrial Cancer: A Systematic Review and Meta-analysis

2016 ◽  
Vol 26 (6) ◽  
pp. 1081-1091 ◽  
Author(s):  
Yun Qin ◽  
Zhizhi Yu ◽  
Jiaxin Yang ◽  
Dongyan Cao ◽  
Mei Yu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Early Stage ◽  
Body Weight Gain ◽  
Meta Analysis ◽  
Live Birth Rate ◽  
Reproductive Age ◽  
Final Sample ◽  
Progestin Treatment ◽  
Early Stage Endometrial Cancer

ObjectiveThis study aimed to evaluate the efficacy and safety of oral progestin treatment for early-stage endometrial cancer.MethodsWe conducted a systematic review and meta-analysis of the proportions from observational studies. Original studies were selected if patients with early-stage endometrial cancer, especially those of reproductive age, were treated with oral progestin. We conducted searches on studies listed in MEDLINE, EMBASE, and Cochrane that were published through June 2014, and relevant articles were also searched. The methodological quality of the included studies was assessed using the Newcastle-Ottawa quality assessment scale. Funnel plots and metaregression analyses were used to assess bias.ResultsThe final sample included 25 articles involving 445 patients. Based on a random-effects model, patients achieved a disease regression rate of 82.4% (95% confidence interval [CI], 75.3%–88.7%), a relapse rate of 25.0% (95% CI, 15.8%–35.2%), a pregnancy rate of 28.8% (95% CI, 22.5%–35.5%), and a live birth rate of 19.6% (95% CI, 12.8%–27.4%). Body weight gain, liver dysfunction, and abnormal blood coagulation test results were the most common treatment-related adverse effects. Only 2 disease-related deaths were reported during the follow-up duration.ConclusionsBased on the present systematic review and meta-analysis, oral progestin treatment is feasible and safe for patients of reproductive age.

The role of genetic and epigenetic changes in the development of atypical hyperplasia and early-stage endometrial cancer

2021 ◽  
Vol 5_2021 ◽  
pp. 48-54
Author(s):  
Gadzhieva L.T. Gadzhieva L ◽  
Pronin S.M. Pronin ◽  
Pavlovich S.V. Pavlovich S ◽  
Kiselev V.I. Kiselev V ◽  
◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Early Stage ◽  
Atypical Hyperplasia ◽  
Epigenetic Changes ◽  
Early Stage Endometrial Cancer
Sign in / Sign up

Export Citation Format

Share Document